natgillin/translations-raw huggingface dataset:
4 pre-filled syringes with needle-trap containing 0.5 ml solution for injection 6 pre-filled syringes with needle-trap containing 0.5 ml solution for injection
6 napolnjenih injekcijskih brizg z varovalnim nastavkom Needle-Trap, ki vsebujejo 0,5 ml raztopine za injiciranje
4 pre-filled syringes with needle-trap containing 0.75 ml solution for injection 6 pre-filled syringes with needle-trap containing 0.75 ml solution for injection
6 napolnjenih injekcijskih brizg z varovalnim nastavkom Needle-Trap, ki vsebujejo 0,75 ml raztopine za injiciranje
4 pre-filled syringes with needle-trap containing 1 ml solution for injection 6 pre-filled syringes with needle-trap containing 1 ml solution for injection
6 napolnjenih injekcijskih brizg z varovalnim nastavkom Needle-Trap, ki vsebujejo 1 ml raztopine za injiciranje
4 pre-filled syringes with safety needle containing 1 ml.
4 napolnjene injekcijske brizge z varnostno iglo, ki vsebujejo 1 ml
4 pre-filled syringes, each containing 40 mg adalimumab 4 alcohol pads
4 napolnjene injekcijske brizge s po 40 mg adalimumaba 4 alkoholni zloženci
4 produced in Vero cells
4 pridobljen v celicah Vero
4 produced in Vero cells
4 pridobljen v celicah Vero.
4 Reconstitution and administration
Rekonstitucija in uporaba
4 Relative to the control arm.
4 Glede na kontrolno skupino.
4 Reports received from post-marketing experience; frequencies calculated, however, on the basis of clinical trial data.
4 po poročilih na podlagi izkušenj z uporabo zdravila po njegovem prihodu na trg, pri čemer so pogostnosti izračunane na osnovi podatkov iz kliničnih preskušanj
4 see also section infusionrelated reactions below.
4 Glejte tudi poglavje reakcije, povezane z infuzijo, spodaj.
4 single-dose pre-filled pens
4 napolnjeni injekcijski peresniki z enkratnim odmerkom
4 spot-on applicators
4 aplikatorji za kožni nanos
4 Study conducted with emtricitabine/rilpivirine/tenofovir alafenamide fixed-dose combination tablet.
4 Študija, opravljena z emtricitabinom/rilpivirinom/alafenamidtenofoviratom s tabletami s fiksno kombinacijo odmerkov.
4 Subject to a p-value boundary of 0.0116.
4 Odvisna od meje p-vrednosti, ki je 0,0116.
4 subjects with evidence of proximal tubulopathy improved without clinical consequence upon discontinuation of Stribild, but did not completely resolve in all subjects.
4 osebah z znaki proksimalne tubulopatije so se po prekinitvi uporabe zdravila Stribild popravili brez kliničnih posledic, vendar pa niso pri vseh osebah povsem izzveneli.
4 syringes
4syringes
4 syringes with needles
4 brizgami z iglami
4 tablets
1 tableta
4 tablets (1 blister strip)
4 tablete (1 pretisni omot)
4 tablets (400/100 mg)
4 tablete (400 mg/100 mg)
4 tablets b
4 tableteb
4 The clinical significance of these in vitro data has not been demonstrated.
4 Klinični pomen teh in vitro podatkov ni bil dokazan.
4 The incidence of diarrhea was 4.1% (36/882) in the saxagliptin 5 mg group and 6.1% (49/799) in the placebo group.
4incidenca driske je bila v skupini s saksagliptinom 5 mg 4,1 % (36/882) in v skupini s placebom 6,1 % (49/799)
4 The incidence of diarrhoea was 4.1% (36/882) in the saxagliptin 5 mg group and 6.1% (49/799) in the placebo group.
4incidenca driske je bila v skupini s saksagliptinom 5 mg 4,1 % (36/882) in v skupini s placebom 6,1 % (49/799)
4 The total duration shown may include intravenous Zavicefta followed by appropriate oral therapy
4 Celotno prikazano trajanje lahko vključuje intravensko uporabo zdravila Zavicefta, ki ji sledi ustrezno peroralno zdravljenje.
4 This adverse reaction was identified through post-marketing surveillance for either efavirenz, emtricitabine or tenofovir disoproxil fumarate.
4 Ta neželeni učinek je bil ugotovljen pri opazovanju po začetku trženja za bodisi efavirenz, emtricitabin ali dizoproksiltenofovirijev fumarat.
4 This study was conducted using elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
4 Ta študija je bila opravljena z elvitegravirjem/kobicistatom/emtricitabinom/dizoproksiltenofoviratom fumaratom.
4 This study was conducted using Stribild.
4 Ta študija je bila opravljena z zdravilom Stribild.
4 times per year, based on clinical considerations, such as baseline renal function, volume depletion, concurrent illness or concomitant medications.
4-krat na leto glede na klinične okoliščine, npr. izhodiščno delovanje ledvic, hipovolemijo, sočasne bolezni ali sočasna zdravila.
4 to less than 6
4 do manj kot 6
4 toxicity (%)
3-4 (%)
4 Unstratified log-rank test
4 Nestratificiran test log-rank
4 vial adaptors
4 adapterji za viale
4 vials
4 vial
4 vials
Škatla s 4 vialami
4 vials +
4 viale +
4 vials + 4 pre-filled syringes + 8
4 viale + 4 napolnjene brizge +8 igel
4 vials + 4 vials
4 viale + 4 viale
4 vials of 1.5 mL solvent
4 viale z 1,5 ml vehikla
4 vials of 10 ml
4 viale z 10 ml
4 vials of 10ml.
4 viale po 10 ml.
4 vials of 2 mg powder
4 viale z 2 mg praška
4 vials of 20 ml
4 viale z 20 ml
4 vials of 4 ml
4 viale s 4 ml
4 vials of powder for solution for infusion
4 viale praška za raztopino za infundiranje
4 vials of powder for solution for injection 4 vials of solvent
viale praška za raztopino za injiciranje 4 viale vehikla
4 vials of powder for solution for injection and 4 ampoules of solvent for injection;
4 viale praška za raztopino za injiciranje in 4 ampule vehikla za injiciranje;
4 vials of powder for solution for injection and 4 ampoules of solvent for parenteral use;
4 viale s praškom za raztopino za injiciranje in 4 ampule z vehiklom za parenteralno uporabo,
4 vials of powder for solution for injection, 4 ampoules of solvent for injection, 4 injection syringes, 8 injection needles and 4 cleansing swabs;
4 viale praška za raztopino za injiciranje, 4 ampule vehikla za injiciranje, 4 injekcijske brizge, 8 injekcijskih igel in 4 čistilni tamponi;
4 vials of powder for solution for injection, 4 ampoules of solvent for parenteral use, 4 injection syringes, 8 injection needles and 4 cleansing swabs;
4 viale s praškom za raztopino za injiciranje, 4 ampule z vehiklom za parenteralno uporabo, 4 injekcijske brizge, 8 injekcijskih igel in 4 čistilni tamponi,
4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs
4 viale praška, 4 ampule vehikla, 4 injekcijske brizge, 8 injekcijskih igel, 4 čistilni tamponi
4 vials of Rilonacept Regeneron powder
4 viale praška zdravila Rilonacept Regeneron;
4 vials of sterile water (solvent)
4 viale sterilne vode (vehikel).
4 vials with Bioset device + 4 pre- filled syringes
4 viale z napravo Bioset + 4 napolnjena brizga
4 week period during treatment (permanent dose reduction)
4-tedenskem obdobju med zdravljenjem (stalno zmanjšanje odmerka)
4 weeks after completion of the primary course for Leptospira components.
4 tedne po zaključku osnovnega cepljenja proti komponentam Leptospira.
4 weeks after stopping treatment
4 tedne po koncu zdravljenja
4 weeks after the completion of primary course for Leptospira components
4 tedne po zaključku osnovnega cepljenja proti komponentam Leptospira.
4 weeks after the completion of primary course for Leptospira components.
4 tedne po zaključku osnovnega cepljenja proti komponentam Leptospira.
4 weeks after your last treatment, then every 4 weeks thereafter.
1 napolnjene injekcijske brizge) 4 tedne po zadnjem zdravljenju, nato vsake 4 tedne
4 weeks for women with childbearing potential
4 tedne za ženske v rodni dobi
4 x (1 vial + 1 pre-filled syringe +
4x (1 viala + 1 napolnjena injekcijska brizga
4 x 0.25 mL injections, or
4 x 0,25 ml injekcije ali
4 x 1 film-coated tablet 8 x 1 film-coated tablet 12 x 1 film-coated tablet
4 x 1 filmsko obložena tableta 8 x 1 filmsko obložena tableta 12 x 1 filmsko obložena tableta
4 x 1 orodispersible tablet: EU/1/09/551/015
4 x 1 orodisperzibilna tableta: EU/1/09/551/015
4 x 1 orodispersible tablet: EU/1/09/551/020
4 x 1 orodisperzibilna tableta: EU/1/09/551/020
4 x 1 orodispersible tablet: EU/1/09/551/025
4 x 1 orodisperzibilna tableta: EU/1/09/551/025
4 x 1 orodispersible tablets
4 x 1 orodisperzibilna tableta
4 x 1 tablet
4x1 tablet
4 x 1 tablets (unit
2 x 1 tableti (enkratni
4 x 1 tablets (unit
4 x 1 tablete (enkratni
4 x 1 tablets (unit
4 x 1 tablete (enkratni odmerek)
4 x 1 tablets (unit dose)
4 x 1 tableta (enkratni odmerek)
4 x 10 doses (20 ml) 4 x 25 doses (50 ml) 4 x 50 doses (100 ml) 6 x 5 doses (10 ml)
4 x 10 odmerkov (20 ml) 4 x 25 odmerkov (50 ml) 4 x 50 odmerkov (100 ml) 6 x 5 odmerkov (10 ml)
4 x 10 ml vials
4 x 10 ml viale
4 x 125 doses
4 x 125 odmerkov
4 x 200 mg tabletsb
4 x 200 mg tabletab
4 x 4 ml vials
4 x 4 ml viale
4 x 50 doses
4 x 50 odmerkov
4 years
leta
4 years (2C – 8C)
4 leta (2 C – 8 C)
4 years for blisters.
4 leta za pretisne omote.
4 years Multidose vial
4 leta Večodmerna viala
4 years).
2,5 let (do 4 leta).
4 years.
leta.
4 – Open the blister pack containing the vial adapter, but leave the vial adapter inside.
4 - Odprite pretisni omot z adapterjem za vialo, vendar ga pustite v omotu.
4 – Take out the pre-filled diluent syringe from its package.
4 - Brizgo, napolnjeno z vehiklom, vzemite iz ovojnine.
4 “Gastrooesophageal reflux disease” term includes gastrooesophageal reflux disease, dyspepsia and gastritis.
4 Izraz »gastroezofagealna refluksna bolezen« vključuje gastroezofagealno refluksno bolezen, dispepsijo in gastritis.
4) in patients with narcolepsy with cataplexy except for trial 2 where cataplexy was not required for enrolment Concomitant stimulant use was permitted in all trials (except for the active-treatment phase of Trial 2); antidepressants were withdrawn prior to active treatment in all trials with the exception of Trial 2.
Sočasna uporaba stimulansov je bila dovoljena v vseh preskušanjih (razen v aktivni fazi zdravljenja pri 2. preskušanju); antidepresivi so bili ukinjeni pred aktivnim zdravljenjem v vseh preskušanjih, razen v 2. preskušanju.
4) or considered
3–4) ali klinično
4, Chemin du Calquet 31057 Toulouse Cedex France
4, Chemin du Calquet 31057 Toulouse Cedex Francija
4, Poligono Industrial Malpica, 50016 Zaragoza Spain
4, Poligono Industrial Malpica, 50016 Zaragoza Španija
4,000 (number of doses per ampoule is presented on the colour coded clip attached to each cane containing the ampoule)
4.000  (Število odmerkov na ampulo je navedeno na oznaki vsakega niza ampul.)
4,000 doses
4,000 odmerkov
4,000 doses
4.000 odmerkov
4,000 doses
4000 odmerkov
4,000 IU
4.000 i.e
4,000 IU/0.4 ml
4.000 i.e./0,4 ml
4,000 IU/0.5 ml and Eporatio 5,000 IU/0.5 ml: Each pre-filled syringe contains 0.5 ml of solution.
4000 i.e./0,5 ml in Eporatio 5000 i.e./0,5 ml: ena napolnjena injekcijska brizga vsebuje 0,5 ml raztopine.
4,000 IU/10 ml
4,000 i.e./10 ml
4,000 – 6,000 IU
4000–6000 i.e.
4,039 (669; 10,897) ng/mL and 39,744 (6,002; 119,770) ng•h/mL for GS-563117, respectively.
4.039 (669; 10.897) ng/ml in 39.744 (6.002; 119.770) ng•h/ml za GS-563117.
4,380 (458 - 59,084)
parameter
4,541 patients undergoing total hip replacement surgery
4.541 bolnikov z zamenjavo kolka
4,800 units*,
4.800 enot*,
4,832 patients with an acute symptomatic PE
4,832 bolnikov z akutno simptomatsko PE
4- 6 times per day in small children).
4–6 krat dnevno pri majhnih otrocih).
4-6 times per day in small children).
4–6 krat dnevno pri majhnih otrocih).
4-ampoule
Nosilec s po
4-hydroxy atorvastatin: AUC: 0 4% (0 0 to 0 31)
AUC: ↓ 4 % (↓ 0 do ↓ 31)
4-week treatment initiation pack
Štiritedensko začetno pakiranje (začetek zdravljenja)
4-week treatment initiation pack containing: 11 x 0.5 mg film-coated tablets and
Štiritedensko začetno pakiranje, ki vsebuje: 11 x 0,5 mg filmsko obloženih tablet in
4-week treatment pack of 252 capsules
Pakiranje za štiritedensko zdravljenje z 252 kapsulami
4. p-value <0.0001.
Vrednost p < 0,0001.
4.) Remove ITLC strip and cut in half at the 3.5 cm cut line.
Odstranite ploščico za ITLC in jo prerežite na pol po oznaki linije reza pri 3,5 cm.
4.0 mg zoledronic acid
4,0 mg zoledronske kisline
4.0%
°C)
4.04 p < 0.0001
p < 0,0001
4.1 ml for 3.3 mg dose
4,1 ml za odmerek 3,3 mg,
4.1 ng/mL (14 to 24 ng/mL) and 8.2  4.2 mg (3.6 to 13.6 mg), respectively (see section 4.2).
4,2 mg (od 3,6 do 13,6 mg) (glejte poglavje 4.2).
4.1% (95% CI: 1.6% to
4,1 % (95 % IZ:
4.1% (95% CI: 1.6% to 6.7%, p < 0.001c)
4,1 % (95 % IZ: 1,6 % do 6,7 %, p < 0,001c)
4.2 % sodium bicarbonate
4,2 % raztopino natrijevega hidrogenkarbonata
4.2 ml solvent Plunger rod Vial adapter
Bat brizge Adapter viale
4.2 mo
Učinkovitost
4.21 (p=0.0048)
4,21 (p = 0,0048)
4.271
zdravljenja
4.28 ml
Vsebina
4.3 and 4.4).
4.3 in 4.4).
4.3 ml once daily
4,3 ml enkrat na dan
4.3 ml twice daily
4,3 ml dvakrat na dan
4.3 Posology and method of administration
Odmerjanje in način uporabe
4.3 Special warnings and precautions for use
Posebna opozorila in previdnostni ukrepi
4.3 ± 1.5
ni podatka 4,3 ± 1,5
4.3).
Pri
4.3. Immunogenicity data in preterm infants
Podatki o imunogenosti pri nedonošenčkih
4.4 and 4.8 Class effects)
in 4.8 odstavek Učinki po skupinah)
4.4 and 4.8).
4.8).
4.4 ml for 3.5 mg dose
4,4 ml za odmerek 3,5 mg
4.4 ml for 3.5 mg dose
4,4 ml za odmerek 3,5 mg,
4.4 months; HR = 0.670; p = 0.1208. A statistically significant improvement in OS was seen in the olaratumab plus doxorubicin arm in comparison to treatment with doxorubicin alone in the overall population.
V celotni populaciji je bilo v skupini, ki je prejemala kombinacijo olaratumaba in doksorubicina, opaženo statistično značilno izboljšanje OS v primerjavi s skupino, ki je prejemala le doksorubicin.
4.4 µg of polysaccharide for serotype 6B
4,4 µg polisaharida serotipa 6B,
4.4).
inducira.
4.4)11
poglavje 4.4)11
4.4)12
poglavje 4.4)12
4.4.
poglavje 4.4
4.4. Special warnings for each target species
Posebna opozorila za vsako ciljno živalsko vrsto
4.4.)
poglavje 4.4)
4.45 ml water for injections
4,45 ml vodaeza injekcije
4.5
klikov
4.5 ml (ethanol 96% and water for injections).
4,5 ml (96 % etanol in voda za injekcije)
4.5 ml twice daily
4,5 ml dvakrat na dan
4.5 ml twice daily
4.5 ml dvakrat na dan
4.5 months (95 % C.I.: 2.9, 9.6) for the cisplatin arm with an hazard ratio of 1.15 (0.59, 2.23).
9,6), razmerje tveganja 1,15 (0,59; 2,23).
4.5. Interaction with other medicinal products and other forms of interaction
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
4.6 (2.8, NR)
4,6 (2,8, ND)
4.6 mg/24 h transdermal patch
4,6 mg/24 h transdermalni obliž
4.6 mg/24 h transdermal patch rivastigmine
4,6 mg/24 h transdermalni obliž rivastigmin
4.6 mg/24 h transdermal patch Rivastigmine 3M Health Care Ltd.
4,6 mg/24 h transdermalni obliž Rivastigmin 3M Health Care Ltd.
4.6 mg/24 h transdermal patch) or 3.5 cm by 2.6 cm (Rivastigmine 3M Health Care Ltd.
4,6 mg/24 h transdermalni obliž) ali 3,5 cm krat 2,6 cm (Rivastigmin 3M Health Care Ltd.
4.6 mg/24 h transdermal patch) or “R10” (Rivastigmine 3M Health Care Ltd.
4,6 mg/24 h transdermalni obliž) ali “R10” (Rivastigmin 3M Health Care Ltd.
4.6 months (BSC), but the difference did not reach statistical significance; hazard ratio 0.88 (95% CI 0.69, 1.12).
4,6 meseca (NPO), vendar rezultat ni dosegel statistične pomembnosti; razmerje ogroženosti 0,88 (95-odstotni interval zaupanja [IZ]: 0,69 – 1,12).
4.8 log10 copies/mL, median CD4+ cell count was 367 cells/mm3, and median CD4+ percentage was 18%.
367 celic/mm3 in mediana odstotka CD4+ je znašala 18 %.
4.8 ml once daily
4,8 ml enkrat na dan
4.8 ml twice daily
4,8 ml dvakrat na dan
4.8. The frequency of ADRs in sJIA patients can be found in Table 2.
Pogostnost neželenih učinkov pri bolnikih s sJIA je prikazana v preglednici 2.
4.8. Undesirable effects
4.8. Neželeni učinki
4.9
Pogosto
4.9%
podatki
4.Put the tablet on the tongue as soon as it is removed from the packaging.
Tableto položite na jezik, takoj ko jo stresete iz ovitka.
4/75 vs.
v pr. s 6/78
40 % (0.4 IU/mL)
40 % (0,4 i.e./ml)
40 % of patients with bone marrow involvement responded compared to 59 % of patients with no bone marrow involvement (p=0.0186).
Na zdravljenje se je odzvalo 40 % bolnikov z infiltracijo kostnega mozga v primerjavi z 59 % bolnikov brez infiltracije kostnega mozga (p = 0,0186).
40 (14-56) mg/kg BID
40 (14-56) mg/kg dvakrat na dan
40 (26.0%)
578 (70,9)b
40 (57.1%)
PASI 75b
40 boulevard de Champaret 38300 Bourgoin Jallieu France
40 boulevard de Champaret 38300 Bourgoin Jallieu Francija
40 Boulevard de Champaret 38300 Bourgoin Jallieu, France
40 Boulevard de Champaret 38300 Bourgoin Jallieu, Francija
40 Boulevard de Champaret 38300 Bourgoin-Jallieu FRANCE
40 Boulevard de Champaret 38300 Bourgoin-Jallieu FRANCIJA
40 Boulevard de Champaret FR-38300 Bourgoin Jallieu France
40 Boulevard de Champaret FR-38300 Bourgoin Jallieu Francija
40 c
41 c
40 capsules
40 kapsul
40 D units
40 enot D
40 doses (20 ml).
40 odmerki (20 ml).
40 doses (20 ml).
40 odmerkov (20 ml).
40 g sachet: do not store above 25 °C.
40 g vrečka Ne shranjujte pri temperaturi nad 25 C.
40 g sachet: do not store above 25 ºC.
40 g vrečka Ne shranjujte pri temperaturi nad 25 C.
40 g sachet: do not store above 25 ºC.
40 g vrečka: Ne shranjujte pri temperaturi nad 25 C.
40 IU of FVIII per kg body weight at intervals of 2 to 3 days.
FVIII na kg telesne mase v intervalih 2 do 3 dni.
40 IU/ml
EU/1/97/030/004
40 IU/ml
EU/1/97/030/019
40 IU/ml
raztopina za injiciranje
40 IU/ml
uspenzija za injiciranje
40 kg x 90 IU/dL/{[2 IU/dL]/[IU/kg]} = 1800 IU.
40 kg x 90 i.e./dl/{[2 i.e./dl]/[i.e./kg]} = 1800 i.e.
40 kg) (see section 4.2).
40 kg) (glejte poglavje 4.2).
40 mg BID > 60 kg
40 mg 2-krat na dan > 60 kg
40 mg eow
40 mg vsak drugi teden
40 mg every other week.
40 mg vsaki drugi teden.
40 mg Humira every other week
40 mg zdravila Humira vsak drugi teden
40 mg Humira every other week
40 mg zdravilaHumira vsak drugi teden
40 mg Humira every other week
40 mg Zdravilo Humira vsak drugi teden
40 mg Humira every other week
Zdravilo Humira 160/80
40 mg Humira every week
40 mg Zdravilo Humira vsak teden
40 mg Humira every week
Humira 40 mg vsak teden
40 mg Humira every week
Zdravilo Humira 160/80 mg n = 159
40 mg sc
40 mg s.c. enkrat na dan
40 mg single dose
enkratni odmerek 40 mg
40 mg single dose taken 12 hours before rilpivirine
40 mg v enkratnem odmerku 12 ur pred odmerjanjem rilpivirina
40 mg single dose taken 2 hours before rilpivirine
40 mg v enkratnem odmerku 2 uri pred odmerjanjem rilpivirina
40 mg subcutaneously once daily
40 mg subkutano enkrat na dan
40 mg tablets are white, oval, biconvex, with a break line and logo T on one side.
40 mg tablete so bele, ovalne, bikonveksne tablete s prelomno zarezo in oznako T na eni strani.
40 mg Trudexa every other week
40mg Trudexe vsak drugi teden
40 mg), it reduces the immune response.
40 mg) zmanjšajo imunski odziv.
40 mg, single dose
očasno
40 mg, single dose
očasno zdravila
40 mg/12.5 mg tablets: White to almost white or pinkish white on one side and pink marbled on the opposite side of two-layer biconvex oval tablet, tablet dimensions 15 mm x 7 mm.
Tablete po 40 mg/12,5 mg: dvoslojne, izbočene, ovalne tablete, bele do skoraj bele ali rožnato-bele barve na eni strani in roza marmorirane na drugi strani, velikosti 15 mm x 7 mm.
40 mg/ml of tildipirosin
40 mg/ml tildipirozina
40 micrograms Adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.50 milligram Al+)
40 mikrogramov adsorbiran na amorfni aluminijev hidroksifosfat sulfat (0,50 miligrama Al+)
40 micrograms PRE-FILLED SYRINGES LABEL
NALEPKA ZA NAPOLNJENO INJEKCIJSKO BRIZGO 40 mikrogramov
40 mL concentrate in a 50 mL vial (clear Type I glass) with stopper (butyl rubber).
40 ml koncentrata v 50-ml viali (prozorno steklo tipa I) z zamaškom (iz butilne gume).
40 ml HDPE-wide-necked bottle, with screwcap with integrated desiccant container(white silica gel), containing either 15, 30, 60, 90 or 100 film-coated tablets per container.
40-ml plastenka s širokim vratom in navojno zaporko za integriranim vsebnikom za sušilno sredstvo (beli silikagel), ki vsebuje bodisi 15, 30, 60, 90 ali 100 filmsko obloženih tablet na vsebnik.
40 ml HDPE-wide-necked bottle, with screwcap with integrated desiccant container(white silica gel), containing either 30, 60, 90 or 100 film-coated tablets per container.
40-ml plastenka s širokim vratom in navojno zaporko z integriranim vsebnikom za sušilno sredstvo (beli silikagel), ki vsebuje bodisi 30, 60, 90 ali 100 filmsko obloženih tablet na vsebnik.
40 mL of water for injections (WFI) should be added using a sterile syringe to reconstitute each vial to provide a 10 mg/mL solution per vial.
S sterilno injekcijsko brizgo je treba vsaki viali dodati 40 ml vode za injekcije, da dobimo raztopino s koncentracijo 10 mg/ml na vialo.
40 ml plastic bottle
40 ml plastenka
40 ml vial
40 ml viala
40 pipettes
40 merilnih kapalk
40 to 59.9 kg
40 do 59,9 kg
40 tubes
40 tub
40 x 1 tablet (unit
40 x 1 tableta (enkratno
40 x 1 tablet (unit
56 x 1 tableta (enkratno
40 x 1 tablet (unit dose)
40 x 1 tableta (enkratno odmerjanje)
40 yrs
40 let
40 μg /ml
40 μg/ml
40 – 50 microgram/24 h).
50 mikrogramov/24 ur).
40% (13%)
metroragija
40% versus delayed Betaferon
40% v primerjavi z odloženim zdravljenjem z zdravilom Betaferon
40,000 IU/1 ml
40.000 i.e./1 ml
40,000 IU/ml:
40.000 i.e./ml:
40,000 units
40.000 enot
40-49 3.3 mg* zoledronic acid
40-49 3,3 mg* zoledronske kisline
40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse reactions.
40-60%, kar lahko poveča tveganje za pojav neželenih učinkov, povezanih z didanozinom.
40-80
40 do 80
40.6% (26/64) remained on bosentan monotherapy during the 24 weeks of study treatment without experiencing PAH worsening.
40,6 % (26/64) jih je ostalo na monoterapiji z bosentanom med 24-tedenskim študijskim zdravljenjem, ne da bi doživeli poslabšanje PAH.
400 (10 cartridges x 40) tablets
400 (10 vložki x 40) tablet
400 (2 x 200) vaccinal baits
400 (2 x 200) cepilnih vab.
400 g sachet – 2 years.
400 g vrečka - 2 leti
400 g sachet – 2 years.
400 g vrečka – 2 leti.
400 g sachet: do not store above 25 °C.
400 g vrečka: Ne shranjujte pri temperaturi nad 25 C.
400 g sachet: do not store above 25 ºC.
400 g vrečka: Ne shranjujte pri temperaturi nad 25 C.
400 GBq (at ART) The volume depends on the quantity of medicines combined with Lumark required for administration by the nuclear medicine doctor.
Prostornina je odvisna od količine zdravil, kombiniranih z radionuklidnim predhodnikom Lumark, ki vam jih mora dati zdravnik nuklearne medicine.
400 IU vitamin E, approximately 200 mg linoleic acid, 110 mg eicosapentaenoic acid (EPA), 210 mg alpha linolenic acid (ALA) and 80 mg docosahexaenoic acid (DHA) per day).
400 i.e. vitamina E, približno 200 mg linolne kisline, 110 mg eikozapentaenojske kisline (EPA), 210 mg alfa-linolenske kisline (ALA) in 80 mg dokozaheksaenojske kisline (DHA) na dan).
400 IU*
400 i.e.
400 IU/ml after reconstitution with 5 ml solvent.
400 i.e./ml po rekonstituciji s 5 ml vehikla.
400 IU/mL after reconstitution)
400 i.e./ml po rekonstituciji)
400 IU/ml after reconstitution).
400 i.e./ml po rekonstituciji).
400 mg (0,2,4 weeks) with MTX
400 mg (0,2,4 tedni) z MTX
400 mg (10 ml) every 12 hours
400 mg (10ml) vsakih 12 ur
400 mg (10 ml) every 12 hours for the first 24 hours
400 mg (10 ml) vsakih 12 ur v prvih 24 urah
400 mg (20 ml) once daily
400 mg (20 ml) enkrat dnevno
400 mg and 200 mg,
odmerek atazanavirja na 400 mg in
400 mg dose of imatinib resulted in decrease in Cmax and AUC(0-∞) by at least 54% and 74%, of the respective values without rifampicin treatment.
400-miligramski odmerek imatiniba, je povzročilo zmanjšanje Cmax oziroma AUC(0-∞) za vsaj 54 % oziroma 74 % zadevnih vrednosti brez zdravljenja z rifampicinom.
400 mg every 12 hours for
400 mg vsakih 12 ur
400 mg once
400 mg enkrat
400 mg once daily n=283 (%)
400 mg enkrat dnevno n=283 (%)
400 mg powder for concentrate
400 mg praška za koncentrat
400 mg single dose (saquinavir/ritonavir 1600/100 mg qd)
400 mg kot enkratni odmerek (sakvinavir/ritonavir
400 mg tablet
400 mg tablete
400 mg three times daily)
Victrelis 400 mg trikrat na dan)
400 mg to be taken as 1 capsule once a day,
400 mg vzamete kot 1 kapsulo enkrat na dan,
400 mg to be taken as 1 tablet once a day,
400 mg vzamete kot 1 tableto enkrat na dan,
400 mg to be taken as 4 capsules once a day,
400 mg vzamete kot 4 kapsule enkrat na dan,
400 mg to be taken as 4 capsules once a day.
400 mg vzamete kot 4 kapsule enkrat na dan,